Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL PROPHYLAXIS; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLINDNESS; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 12844254962     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421953     Document Type: Article

References (16)

1. Marr KA. Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2001; 14:423-6.
2. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002; 34:1386-90.
3. Dykewicz CA, Jaffe HW, Spira TJ, et al. Guidelines for preventing opportunistic infections among hematopoietic cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation [abstract]. MMWR Morb Mortal Wkly Rep 2000; 49(RR-10):1-125.
4. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
5. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79:250-60.
6. Herbrecht R, Denning DW, Patterson TF, et al. Randomized comparison of voriconazole and amphotericin B in primary therapy for invasive aspergillosis: a collaborative study of the EORTC Invasive Fungal Infections Study Group and the Global Aspergillus Study Group. N Engl J Med 2002; 347:408-15.
7. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
8. Maertens J, Verhaegen J, Lagron K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-10.
9. Winston D, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
10. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-33.
11. Osowski CL, Dix SP, Lin LS, et al. Evaluation of the drug interaction between high-dose (400 mg/day) IV fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61:1268-72.
12. Ghahramani P, Romero AJ, Wood ND, et al. The effect of voriconazole on the pharmacokinetics of cyclosporin [abstract 845]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:24.
13. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus [abstract A-20]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:2.
14. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 34:909-17.
15. Groh WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillosis infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
16. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.